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Abstract Regular use of b2-agonists might result in increased bronchial hyper-responsiveness (BHR) and decreased
forced expiratory volume in1sec (FEV1). It has been suggested thatthese possible detrimental e¡ects are not a real de-
teriorationofthe disease, butthatitmightbeonlyatransient (rebound) e¡ect shortlyafterdiscontinuing thisregularuse.
Moreover, these e¡ects are thought to occur especially during short-acting and notduring long-acting b2-agonists use.
The aim of this study was to investigate whether a rebound e¡ect ( a pharmacological deterioration e¡ect diminishing
after several hours) in FEV1and PC20 (concentration of histamine causing a 20% fall in FEV1with regard to baseline) oc-
curredaftercessationofregularuseof b2-agonists, andwhether thisoccurredbothafter short-actingandlong-acting b2-
agonists. Allergic asthmatic patients (n=134) were randomly allocated to the use of a short-acting (salbutamol), a long-
acting b2-agonist (formoterol) orplacebo for12 weeks (double-blind, double-dummy).No other asthmamedicationwas
allowed, includinginhaledcorticosteroids.Atthe start andevery 4weekslater FEV1and PC20weremeasured, eachtime
at least 12 h after the last doses of study medication, which is in the possible rebound period.To investigate whether a
(transient) rebound e¡ect occurred, parameters were additionallymeasured at least 72 h later after discontinuation of
the studymedication. After12 weeks of short-acting b2-agonist use, a drop was seen in FEV1 from 85?6(72?21)% pre-
dictedto 78?8 (72?9)% predicted, measured15 h (median) after thelastdosesofmedication.Thiswas signi¢cantly di¡er-
entcomparedtoplacebo.Whenmeasured168 h (median) later FEV1recoveredto 85?5 (72?4)%predicted, comparableto
baseline.PC20 decreasedwith1?17 (70?44) doublingdose after12weeksof short-acting b2-agonistuse, measured15 h
after the last doses of medication, whichwas signi¢cantly di¡erent compared to placebo.However,168 h later PC20 re-
covered slightlywith +0?55 (70?34) doublingdose, butthis valuewas stilllowercomparedtoplacebo.In contrast, during
long-actingb2-agonist andplacebouseno signi¢cantchangeswere seen.Inconclusion, theuseof short-acting b2-agonists
resulted in a transient (rebound) e¡ect in FEV1while the e¡ects on PC20 maypointto a real deterioration ofthe disease.
Long-acting b2-agonist andplacebouse showedno changes.We concludethat amono-therapyof short-actingandnotof
long-acting b2-agonistsmighthave deleterious e¡ects in asthma.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1243, available online athttp://www.idealibrary.comon
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In the last 5^10 years, interest in the possibly detrimen-
tal e¡ects of chronic b2-agonist use for treating asthmaReceived 28 June 2001, accepted in revised form 2October 2001and
published online18 January 2002.
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C.vanWeel@hsv.kun.nlhas increased. It started with the observation that the
increase in asthma deaths may have been causally asso-
ciated with treatment with b2-agonists (1,2). Moreover,
several studies observed adverse e¡ects during regular
b2-agonist use, such as increased bronchial hyper-
responsiveness (3^5), increased decline in lung function
(6) or decreased overall control of asthma (7).Other stu-
dies have suggested that patients may be most sensitive
in the period a few hours after cessation of b2-agonist
treatment since bronchial responsiveness has shown to
156 RESPIRATORYMEDICINEincrease (3^5,8,9) and forced expiratory volume in 1sec
(FEV1) to decrease at this time (5,7,9), while these e¡ect
diminished several hours later (4,9). This period shortly
after cessation is referred to as the rebound period
(4,9). Studies that reported a deterioration in bronchial
hyper-responsiveness (BHR) or FEV1 during regular use
of a b2-agonist, usually measured these parameters a
few hours after the last doses of the short-acting b2-
agonist, to avoid still existing bronchodilatating e¡ects
of these b2-agonists (functional antagonism). It has been
suggested that this observed deterioration is not a real
deterioration of the disease due to regular b2-agonist
use, but merely the result of measuring in this rebound
period. It is thought that this rebound e¡ect is largely ex-
tinguished after 72h.Moreover, it hasbeenhypothesized
that this rebound e¡ect especially occurs after the regu-
lar use of short-acting b2-agonists and not after the use
of long-acting b2-agonists (10,11).
In this study we investigated the e¡ects of regular use
of short-acting and long-acting b2-agonists for 12 weeks
in allergic asthmatic patients. Patients were not allowed
to use inhaled corticosteroids, so that the isolated ef-
fects of regular b2-agonists use could be assessed. Sub-
jects were measured each time at least 12h after the
last dose of study medication, so each time in the possi-
ble rebound period. We additionally investigated what
the development is in these parameters, after a longer
cessation period (at least 72h).Therefore, at the end of
the12-week studymedication period FEV1and PC20 (the
concentration of histamine causing a 20% fall in FEV1with
regard to baseline) were measured an extra time, at
least 72h after discontinuing the study medication, to
avoid possible rebound e¡ects. By adding this last mea-
surements, we are able to determine whether possibly
detrimental e¡ects of short-acting b2-agonists are only
due to a rebounde¡ect and are notre£ecting a realwor-
sening of asthma.
METHODS
Patients
Asthmatic patients were selected by their GP for this
study. They used no inhaled steroids or were able to
cease this medication, to study the isolated e¡ects of
chronic use of b2-agonists and the e¡ects of discontinu-
ing this medication. Selection procedures were de-
scribed in detail elsewhere (12). The Medical Ethical
Committee of theMedical CentreDekkerswald,Univer-
sityofNijmegen, approved the studyprotocol, and all pa-
tients gave awritten informed consent.
Design
This study was a randomized, double-blind, double-dummy,
placebo-controlled clinical trial of 12?5 weeks. Selectedpatients were randomly allocated to the use of a short-
acting [salbutamol (mdi), 200mg qid] or long-acting [for-
moterol (mdi), 12mg bid] b2-agonist, or placebo,
resulting in three study-groups (Fig. 1). Patients started
with a 4-week run-in period, in which no changes took
place. After this period patients ceased all their pulmon-
ary medication if used (inhaled corticosteroids, cromo-
glycates, bronchodilators, etc) and were instructed to
use only the rescue medication on demand (Beroduals,
Boehringer Ingelheim Alkmaar,The Netherlands). Bero-
duals was chosen because it predominantly contains
ipratropium bromide (40mg, anti-cholinergic bronchodi-
lator) and a lowdose of fenoterol hydrobromide (100mg).
So, use of b2-agonsists as rescue medication was pre-
vented as much as possible during the study.The amount
of bronchodilator usage was carefully recorded. This was
followed by an 8-week washout period, to adjust patients
to the cessation of their medication. After these 8 weeks
patients received the studymedication (double-blind, dou-
ble-dummy) andwere instructed to use themedication for
12 weeks (rescuemedication usewas still allowed andwas
carefully recorded). After this 12-week study period, sub-
jects discontinued the use of the study medication and
were instructed to use no b2-agonists until the nextmea-
surement at the lung function laboratory, which was at
least 72h after the last dose of studymedication.
Lung functionmeasurements
Spirometry and bronchial hyper-responsiveness (BHR)
weremeasured during inclusion, at the start of the study
medication period and after every 4 weeks of follow-up,
each time at least12h after the lastdose of studymedica-
tion.Furthermore, at the end of the12-week studymed-
ication period an additional measurement was done at
least 72h after the last dose of study medication. Spiro-
metric parameters (FEV1, reversibilityof FEV115min after
inhaling 400mg of salbutamol) were measured by means
of a Microspirometer (HI-298, Chest Corporation, To-
kyo, Japan) (13). Reversibility of FEV1 was calculated as
percentage of the pre-bronchodilator value.
BHRwas determinedby stepwise inhalation of increas-
ing concentrations of histamine solution, according to
the ERS standard (tidal breathingmethod) (14).Doubling
concentrations of histamine acidphosphate, from 0?03 to
16?0mgml1were administered.The concentration of in-
haled histamine, causing a 20% fall in FEV1with regard to
baseline (PC20histamine) was obtained from the log-con-
centration response curve by linear interpolation. After
spontaneous recovery to 90% or more of the pre-hista-
mine value, bronchodilator response was measured be-
fore and15min after 400mg salbutamol (mdi).
Analysis
PC20 values were
2log transformed to achieve a normal
distribution. Di¡erences could then be interpreted as
FIG. 1.
COMPARISONBETWEENSHORT-ACTINGANDLONG-ACTING 157doubling doses. FEV1 is presented as percentage of the
predicted value (ERS/ECSC standard) (15). Measure-
ments at the start of the medication period served as
baseline values (week 0). Di¡erences between week 0
andweek12, week12 andweek13, andweek13 andweek
0 were calculated. It was tested whether these changes
di¡ered between the three medication groups by Stu-
dent’s t-test.Next, within eachmedication group, values
were compared by Student’s paired t-test (week 0 vs.
week 12, week 12 vs. week 13 and week 0 vs. week 13).
Changes are presented as mean (7SEM), and the signi¢-
cance level was set at 5%.
RESULTS
Patients
Two hundred and four patients started thewashout peri-
od (Table 1). During this period 42 subjects dropped out,
consequently162 patients started the medication period.
During this medication period ¢ve subjects dropped-out
because they had to restart their IC use before the ¢rst
follow-up measurement (short-acting: 2, long-acting: 0,
placebo: 3). Five subjects stopped taking the study medi-
cation within 4 weeks after the start (short-acting: 2,
long-acting: 1, placebo: 2). Seven patients dropped out
due tomotivational factorswithin 4weeks after the start
(short-acting: 5, long-acting: 1, placebo: 1). Consequently
those 17 subjects performed only the baseline measure-ment, and 145 subjects completed the study medication
period.Of these145patients,134underwent themeasure-
ment at least 72h after discontinuing b2-agonists, 44 in
the short-acting b2-agonists group, 46 in the long-acting
b2-agonists group and 44 in the placebo group.The other
11patients were not able to do this measurement, due to
planning problems (e.g. work, holiday) or due to motiva-
tional problems.There was no selective dropout. Patient
characteristics of these 134 patients are presented in
Table 2. There were no di¡erences between the three
groups in baseline characteristics.
Time after discontinuing studymedication
and rescuemedication
The median hours of discontinuing the rescue medica-
tion before eachmeasurements was15h (25^75 percen-
tile: 12^17h) for the short-acting group, 15h (25^75
percentile: 14^18h) for the long-acting group and 15h
(25^75 percentile: 12^18?5h) for the placebo group.
These data con¢rm that during regular use of the study
medication (week 0 t/m week 12), patients were mea-
sured in the possible rebound period. They were mea-
sured on average 168h (25^75 percentile: 144^192h)
later after discontinuing this use (week 13), which is as-
sumed to be outside the rebound period.
There was no excessive use of rescue medication
in each of the three study groups (Table 3). Moreover,
TABLE 1. Numberof subjects and drop-outs during the study
Studyperiod
Start
washout
Start
medication
period
End
medication
period
Oneweek
after
discontinuing
No of patients remained inthe study 204 162 145 134
No drop-outs in precedingperiod 42 17 11
Lackofmotivation/planningproblems 19 7
Deterioration of asthma (need of inhalation corticosteroids) 23 5
Stoppedusing studymedication 5
TABLE 2. Baseline characteristics ofthe threemedication groups.Means (and standard deviation) are given
Short-acting Long-acting Placebo P-value
(n=44) (n=46) (n=44)
Gender (M/F) 26/18 22/24 22/22 0?529
Age (yrs) 34?3 (9?8) 33?1 (11?6) 36?2 (11?9) 0?402
Height (cm) 176?7 (10?0) 175?8 (8?3) 174?3 (8?9) 0?460
PC20*(mgml1) 1 ?09 (0?582?04) 1?08 (0?631 ?86) 1?23 (0?682?20) 0?948
FEV1 (% reference) 85?6 (14?7) 83?6 (15?2) 81?1 (18?6) 0?447
Reversibilityw 12?0 (5?117?7) 12?5 (5?520?3) 13?4 (7?925?2) 0?366
*Geometricmean (95% con¢dence interval).
wMedian (25^27 percentile), testedwith Kruskal^Wallis.
TABLE 3. Use of 40 mg ipratropiumbromide plus 100 mg fenoterol in numbers of capsules (of Beroduals) per day presented as
median (inter-quartile range) testedwith Kruskal^Wallis
Short-acting Long-acting Placebo P-value
Wash-out 0?10 (0?001?00) 0?09 (0?000?41) 0?25 (0?001?13) 0?573
0^4 weeks 0?00 (0?000?52) 0?00 (0?000?39) 0?04 (0?000?38) 0?853
4^8 weeks 0?00 (0?001?10) 0?00 (0?000?39) 0?05 (0?000?79) 0?385
8^12 weeks 0?07 (0?001?00) 0?00 (0?000?21) 0?02 (0?000?65) 0?173
12^13 weeks 0?00 (0?001?00) 0?00 (0?000?21) 0?00 (0?000?43) 0?578
158 RESPIRATORYMEDICINEthe use of rescue medication was also discontinued
at an appropriate time before each measurement
(Table 4).
Changes in FEV1and PC20
The drop in FEV1 from week 0 to week 12 in the short-
acting b2-agonists group was signi¢cantly greater com-
pared with the drop in the placebo group in this period
[di¡erence 5?4 (72?4)% predicted, P=0?026, see Fig. 2].
After1week of discontinuing of studymedication, an in-
crease in FEV1 compared to week12 was observed.This
increase was signi¢cantly greater compared to this in-
crease in theplacebo group [di¡erence: 5?2 (72?1)% pre-
dicted, P=0?015].PC20 decreased after12 weeks of short-acting b2-ago-
nist use.This decreasewas signi¢cantly greater than the
decrease after placebo use in this period [di¡erence:1?06
(70?47) doubling dose, P=0?032, see Fig. 3]. After 1
week of discontinuing this study medication an increase
in PC20 compared to week 12 was observed of 0?55
(70?34) doubling doses, while the placebo group
showed a decrease in this period [0?58 (70?31) dou-
bling dose].These changes fromweek12 toweek13 were
signi¢cantly di¡erent [1?13 (70?46) doubling dose,
P=0?016] between the short-acting b2-agonist and
placebo group.
Therewere no di¡erences in changes in FEV1and PC20
between placebo and long-acting b2-agonist use, for
both the period week 0 to week 12 (15h after the last
dose), and the periodweek12^week13 (1week after dis-
continuing).
TABLE 4. Number of patients using 40 mg ipratropiumbromide plus 100 mg fenoterol in each medication group and number of
hours of discontinuing 40 mg ipratropiumbromide plus100 mg fenoterol (median+25^75 percentile) before eachmeasurement, by
these patients (99 means 40 mg ipratropiumbromide plus100 mg fenoterol discontinued longer than 99 h)
Week 0 Week 4 Week 8 Week12 Week13
Short-acting (n=44) n=28 n=18 n=19 n=24 n=15
85?5 h 44?0 h 36?0 h 44?0 h 18?0 h
(17?399?0) (18?099?0) (9?099?5) (10?599?0) (11?099?0)
Long-acting (n=46) n=31 n=15 n=18 n=18 n=9
72?0 h 38?0 h 99?0 h 85?0 h 44?0 h
(16?099?0) (15?099?0) (48?099?0) (48?099?0) (14?099?0)
Placebo (n=44) n=29 n=21 n=26 n=18 13
99?0 h 40?0 h 99?0 h 25?0 h 18?0 h
(45?099?0) (13?599?0) (15?099?0) (14?591?5) (11?599?0)
FIG. 2. FEV1% predicted (FSEM) during the studymedication
period and1week afterdiscontinuing the studymedication, pre-
sented as changes compared to baseline. P-values within groups
are presented. (a) Short-acting (&) vs. placebo (&), (b) long-
acting (&) vs. placebo (&).
FIG. 3. PC20 [doubling doses (FSEM)] during the studymedi-
cation period and 1week after discontinuing the study medica-
tion, presented as changes compared to baseline. (a) Short-
acting (&) vs. placeto (&), (b) long-acting (&) vs. placebo (&).
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week 0 to week 12 in the short-acting b2-agonist group
was signi¢cantly greater when compared with this
change in the long-acting b2-agonist group in this period
[di¡erence: 6?0 (72?4)% predicted, P=0?016). After 1
week of discontinuing the study medication, FEV1 in the
short-acting b2-agonist group increased with
6?7 (71?8)% predicted fromweek12 to week13.This in-
crease was also signi¢cantly greater when comparedwith the long-acting group (di¡erence: 5?6 (72?2)% pre-
dicted, P=0?013). PC20 decreased with 1?17 (70?44)
doubling doses fromweek 0 to week12 in the short-act-
ing b2-agonist group. The long-acting b2-agonists group
showed an increase in PC20 to 0?24 (70?28) doubling
doses in this period, which was signi¢cantly di¡erent
from the decrease in the short-acting group (di¡erence:
1?42 (70?51) doubling dose, P=0?007). After 1 week of
discontinuing the study medication (week 12^week 13),
PC20 increased in the short-acting b2-agonist group and
160 RESPIRATORYMEDICINEdecreased in the long-acting b2-agonist group [di¡er-
ence:1?33 (70?51) doubling dose, P=0?011].
DISCUSSION
This study showed that after regular use of short-acting
b2-agonists for 12 weeks, FEV1 was decreased, when
measured shortly after discontinuing this medication.
However, when this medication was discontinued
for 168 h, values returned to baseline. This indicated a
transient (rebound) e¡ect in FEV1 shortly after
discontinuing short-acting b2-agonists, which disap-
peared after several hours (in this case a median of
168 h). PC20 showed a decrease during regular use of
short-acting b2-agonists as well, when measured
shortly after the last dose. However, after 168h of dis-
continuing, PC20 values are still signi¢cantly lower. So,
this deterioration in PC20 seems not only a result of a
rebound e¡ect, butmight be a re£ection of a real dete-
rioration of the disease during regular use of short-act-
ing b2-agonists. These e¡ects were not seen during
long-acting b2-agonist use and also not during placebo
use for FEV1.
Wahedna et al. (9) showed a fall in FEV1 after 11h of
cessation of albuterol, which recovered after 59h.
Additionally, he showed an increase in BHR after cessa-
tion of b2-agonists use, but this lasted for at least 59 h
(9).Our study clearly con¢rms the ¢ndings of Wahedna
et al. on FEV1values and PC20 values during a prolonged
period, as we found that this decrease in PC20 was
even still present after 168h. Therefore, it is question-
able whether there is only a rebound decrease in
PC20 after discontinuing regular short-acting b2-
agonist use.These results might indicate that there is a
more persistent increase in bronchial hyper-respon-
siveness after regular use of b2-agonists use or in
other words, it might point to a real deterioration of
the disease due to the regular use of short-acting
b2-agonists.
It has been hypothesized before, that a rebound in-
crease in BHR exclusively occurs after regular use of
short-acting b2-agonists (10). Both Cheung et al. (16) and
Yates et al. (17) found no rebound increase in BHR during
regular long-acting b2-agonists use of salmeterol and for-
moterol, respectively, while Vathenen et al. (4) and
Wahedna et al. (9) showed a rebound increase in BHR
after regular short-acting b2-agonists use of respectively
terbutaline and albutamol.These studies did not directly
compare the e¡ects of both short-acting and long-acting
b2-agonists use, and have di¡erent study designs, which
makes a direct comparison di⁄cult. In our study we did
compare theuse of those two types of b2-agonists in the
same study, and we clearly con¢rm these observations.
These ¢ndings are probably of clinical importance,
although no clear pathophysiological mechanism can ex-plain them at the moment. An anti-in£ammatory e¡ect
of long-acting b2-agonists has been suggested (18,19), and
this absence of deleterious and rebound e¡ects during
long-acting b2-agonist use might be an argument in fa-
vour of some anti-in£ammatory properties of long-act-
ing b2-agonists. Moreover, in this study we observed
that the PC20 increased during long-acting b2-agonists
use and dropped signi¢cantly after discontinuing this
medication for 168h, which might also support this sug-
gestion.
The time of measurement after the last doses of
study medication might theoretically have in£uenced
our data. Patients had to discontinue their medication
for at least 12 h during the study medication period. It
has been suggested in literature that long-acting b2-
agonists have e¡ects beyond 12 h (20). So, it might be
that in the long-acting b2-agonist group medication
was still partly active at the time of measurement,
which might result in slightly elevated values.The med-
ian time of stopping the study medication in the total
long-acting b2-agonists group was 15 h at all occasions.
To get an indication whether long-acting b2-agonists
were active during themeasurement15 h after disconti-
nuing, we analysed subjects that stopped their medica-
tion for at least 24 h at week 12 separately. Analyses of
these subgroups did not result in di¡erent ¢ndings, im-
plicating that the b2-agonist activity was probably mar-
ginal at the time of measurement for the whole long-
acting b2-agonist group.
In this study we measured only twice after disconti-
nuing b2-agonists, shortly after discontinuing and a
median of168h after discontinuing, and not repeatedly.
Furthermore, wemeasured subjects not exactly at the
same time schedule, so inter-individual variation
was possible. In the studies of Vathenen et al. (4) and
Wahedna et al. (9), all subjects were measured several
times after cessation of b2-agonists and all patients
were measured exactly at the same time after cessa-
tion.Therefore, in those studies it was possible to eval-
uate the time-response curve of measured parameters
after discontinuing b2-agonists. Although this has not
been done in our study, we have performed an addi-
tional analysis on patients that discontinued short-act-
ing b2-agonists at least 72h, but shorter than 168h,
and patients that discontinued this drug longer than
168 h. Both the ‘short’ stoppers and the ‘long’ stoppers
showed the same tendency on changes in FEV1 and
PC20, as was shown here for the total short-acting b2-
agonist group. Therefore the negative e¡ect on PC20
was even present in patients measured more than
168 h (1 week) after discontinuing the short-acting b2-
agonists.This con¢rms that the e¡ects on FEV1 are re-
versible and that e¡ects on PC20might re£ect a real de-
terioration.
The rebound decrease in FEV1 shortly after the last
dose of short-acting b2-agonists, is thought to be due to
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muscles (21,22).The increase in BHRmight also be a re-
sult of this phenomenon, but may also be due to b2-re-
ceptor down-regulation on in£ammatory cells such as
mast cells (21,22).This latter phenomenon is thought to
result in reduced protection (tolerance) against direct
and indirect stimuli, resulting in increased in£ammation
(21). The latter hypothesis might explain why FEV1 re-
covers after168h andwhy BHRdoes not.The down-reg-
ulation on the smooth muscle might recover quicker
than on in£ammatory cells. In other words the rebound
e¡ect in FEV1 suggest that the e¡ects of regular b2-ago-
nists seems to point to amorepharmacological cause for
FEV1, whereas the e¡ects on PC20 seems more than a
pharmacological phenomenon alone: an increase in in-
£ammation with a longer duration seems to have oc-
curred.
In this study we assessed the e¡ects of b2-agonists use
alone.Therefore, use of other asthma medication, espe-
cially inhaled corticosteroids, was not possible. In this
way we could investigate the isolated e¡ects of b2-ago-
nist, during regular use and also after stopping this use.
Because regular treatment with b2-agonists is not ad-
vised as a mono-therapy in guidelines, but only with ad-
ditional treatment of inhaled corticosteroids, it is
interesting to know what these e¡ects arewhen inhaled
corticosteroids are used at the same time.The possible
down-regulation of b2-receptors is thought to be re-
versed or even prevented by treatment with (inhaled)
glucocorticoids, probably because it increases b2-recep-
tor transcription in human lung (23). This in turn might
prevent the possible detrimental e¡ects during or after
cessation of regular b2-agonist use. In a follow-up which
was recently published (12), we could show that the per-
ception of bronchoconstrictionwas improved during ad-
ditional use of inhaled steroids.
In summary, this studydirectly compared cessation of
regular use of short-acting and long-acting b2-agonists.
It was found that a rebound decrease of FEV1 and
increase in BHR occurred, when measured a few
(14^17) h after cessation of short-acting b2-agonists.
However, the deterioration in FEV1was recovered after
168 h while the increase in BHR was still present after
168 h, which might indicate a real deterioration of the
disease. These e¡ects were not seen after cessation of
regular use of long-acting b2-agonists and placebo.
Long-acting b2-agonists seem to have a di¡erent e¡ect
on bronchial hyper-responsiveness than short-acting
b2-agonists.
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